MSB 1.38% $1.47 mesoblast limited

Cell Therapy News/Articles, page-4301

  1. 11,474 Posts.
    lightbulb Created with Sketch. 511
    Yes agree, surely with more on the line they'll beat that timeline?

    As if Remestemcel-L trial delivers results similar to Mt Sinai twelve patient research study then life is in jeopardy not a shortened hospital stay.

    Someone dying while they're in committee won't be accepted by the public imo.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.